Table 4 Pharmacokinetic model-based estimate for cumulative MeHg exposure by diagnostic group
| Â | Area under the curve (ppb) | |||||
|---|---|---|---|---|---|---|
| Â | 2nd and 3rd trimesters | Gestational period | ||||
| Â | ASD | DD/AtD | TD | ASD | DD/AtD | TD |
Number | 153 | 32 | 53 | 153 | 32 | 53 |
Method 1a | Â | Â | Â | Â | Â | Â |
Median | 133 | 140 | 140 | 219 | 262 | 203 |
95th % | 428 | 360 | 408 | 693 | 580 | 680 |
Range | 0 - 545 | 0 - 378 | 0 - 443 | 0 - 1231 | 0 - 654 | 0 - 702 |
Method 2b | Â | Â | Â | Â | Â | Â |
Median | 144 | 149 | 152 | 241 | 286 | 218 |
95th % | 438 | 388 | 407 | 732 | 680 | 688 |
Range | 0 - 1395 | 0 - 487 | 0 - 523 | 0 - 1703 | 0 - 713 | 0 - 800 |